Use of a new anti-inflammatory agent, bucloxic acid, in the treatment of chronic glomerular nephropathies.
D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001806:Blood Urea Nitrogen; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D003510:Cyclohexanes / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D005921:Glomerulonephritis / Q000188:drug therapy*; D006417:Hematuria / Q000188:drug therapy; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D007651:Keto Acids / Q000009:adverse effects / Q000627:therapeutic use; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000188:drug therapy; D010654:Phenylbutyrates / Q000009:adverse effects / Q000627:therapeutic use*; D011507:Proteinuria / Q000188:drug therapy; D013997:Time Factors; D014527:Uric Acid / Q000097:blood
D000893:Anti-Inflammatory Agents; D003510:Cyclohexanes; D007651:Keto Acids; D010654:Phenylbutyrates; D014527:Uric Acid; D003404:Creatinine; D007213:Indomethacin